FDG-PET/CT alters treatment in node-positive penile cancer
Phase 2
- Conditions
- Penile cancerCancer
- Registration Number
- ISRCTN49141161
- Lead Sponsor
- Skåne University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Node-positive penile cancer (cN+ or cN3 after sentinel node biopsy)
Exclusion Criteria
Age below 18 years
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does FDG-PET/CT imaging reveal in node-positive penile cancer progression?
How does FDG-PET/CT compare to conventional imaging for treatment planning in penile squamous cell carcinoma?
Which biomarkers correlate with FDG-PET/CT response patterns in penile cancer metastasis detection?
What adverse events are associated with FDG-PET/CT guided therapy modifications in penile cancer patients?
Are there combination approaches involving FDG-PET/CT and targeted therapies for penile cancer staging?